On September 1, Kossel Medical Technology Co., Ltd. announced the completion of Series C financing of 400 million yuan. This round of financing was jointly led by Shenzhen Venture Capital and Jinhe Capital, followed by Frontier Investment and Chuangjing Capital. Old shareholders such as Su Venture Capital, Su Gaoxin Financial Holdings, Su Gaoxin Shares, and Yueyin Medical Fund continued to be added in excess. Xiqiao Capital acted as financial adviser for this round of financing. The financing will mainly be used to expand production capacity and promote the development and global registration of core products such as peripheral intervention, coronary intervention, and cardiac electrophysiology.

On September 1, Kossel Medical Technology Co., Ltd. announced the completion of Series C financing of 400 million yuan. This round of financing was jointly led by Shenzhen Venture Capital and Jinhe Capital, followed by Frontier Investment and Chuangjing Capital. Old shareholders such as Su Venture Capital, Su Gaoxin Financial Holdings, Su Gaoxin Shares, and Yueyin Medical Fund continued to be added in excess. Xiqiao Capital acted as financial adviser for this round of financing. The financing will mainly be used to expand production capacity and promote the development and global registration of core products such as peripheral intervention, coronary intervention, and cardiac electrophysiology.